July 19, 2024 – Isaac Health, a leading national provider of brain health and dementia care, and Pearl Health, a leading technology company focused on physician enablement in value-based care, are excited to announce a strategic partnership to deliver the CMS Guiding an Improved Dementia Experience (GUIDE) Model to Traditional Medicare beneficiaries aligned with Pearl’s …
July 2, 2024 – The U.S. Food and Drug Administration (FDA) has approved donanemab, a groundbreaking treatment for Alzheimer’s disease. Branded as Kisunla™ (pronounced kih-SUHN-lah) by Eli Lilly, donanemab is an amyloid plaque-targeting therapy for persons living with mild cognitive impairment (MCI) or in the mild dementia stage of Alzheimer’s disease with confirmed amyloid pathology. …
FDA Approval of Donanemab Marks Major Advance in Alzheimer’s Treatment Read More »
NEW YORK, New York, July 1, 2024 – Isaac Health, a leading national telehealth provider of brain health and dementia care, is a participant in the Centers for Medicare & Medicaid Services’ (CMS) Guiding an Improved Dementia Experience (GUIDE) Model, launching today. This program enables Isaac Health to deliver comprehensive, personalized care to individuals living …
Isaac Health Joins CMS GUIDE Model Program to Enhance Dementia Care Nationwide Read More »
NEW YORK, April 17, 2024 – Isaac Health, a leading national provider of brain health and dementia care, is thrilled to expand their existing relationship with New York-headquartered CaringKind to offer individuals and families affected by dementia new support provided through the Centers for Medicare & Medicaid Services’ (CMS) Guiding an Improved Dementia Experience (GUIDE) …
NEW YORK, New York, April 9, 2024 – Isaac Health, a leading national provider of brain health and dementia care, has been accepted in the established and new model tracks of the Centers for Medicare & Medicaid Services’ (CMS) Guiding an Improved Dementia Experience (GUIDE) Model. The GUIDE Model focuses on enhancing care for individuals …
Isaac Health is an accepted participant in CMS GUIDE Model Program Read More »
Isaac Health, a digital health company emerging as a national leader for brain health, announced today the successful completion of its oversubscribed $5.7 million Seed round. The round was led by Meridian Street Capital and B Capital with participation from Primetime Partners, Co-Found Partners, VU Venture Partners, and AirAngels.
The Centers for Medicare & Medicaid Services (CMS) has launched a new dementia care management program called GUIDE (Guiding an Improved Dementia Experience). This program is designed to improve the quality of care and support for people living with dementia and their caregivers. Isaac Health is a proud participant in the GUIDE Model right from …
CMS Launches New Dementia Care Management Program Read More »
Introduction: The recent full approval of Lecanemab (Leqembi) by the FDA has ushered in a new era in the treatment of Alzheimer’s disease. As the first disease-modifying treatment to receive such approval, Leqembi offers hope to patients with early-stage Alzheimer’s. However, its adoption poses cost implications for payers and risk-bearing health systems. In a newly …
Introduction: On July 6, 2023, the FDA granted full approval to Lecanemab (Leqembi), marking a significant milestone as the first disease-modifying treatment for Alzheimer’s disease to receive such approval. This white paper aims to inform health insurance employees about the implications of Leqembi’s approval and offer insights into coverage considerations and potential cost implications. Coverage …
Leqembi – Implications for Health Insurance Payers: A Comprehensive Analysis Read More »
About Leqembi Leqembi is the first of (very likely) many forthcoming drugs that will be revolutionizing the landscape of early stage Alzheimer’s disease. With its traditional (full) FDA approval come new questions from our patients and community surrounding its availability, manufacturer, purchasing options, working mechanism, insurance coverage, and comparisons with other medications. Our doctors here …
